Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 2636701, 10 pages
http://dx.doi.org/10.1155/2016/2636701
Review Article

Metabolism Is Central to Tolerogenic Dendritic Cell Function

1Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore 138673
2Institute of Biomedical Studies, Baylor University, Waco, TX 76712, USA

Received 7 November 2015; Accepted 31 December 2015

Academic Editor: Jurjen Tel

Copyright © 2016 Wen Jing Sim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Ueno, E. Klechevsky, R. Morita et al., “Dendritic cell subsets in health and disease,” Immunological Reviews, vol. 219, no. 1, pp. 118–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Xing and K. A. Hogquist, “T-cell tolerance: central and peripheral,” Cold Spring Harbor Perspectives in Biology, vol. 4, no. 6, pp. 1–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Yamazaki, D. Dudziak, G. F. Heidkamp et al., “CD8+CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells,” The Journal of Immunology, vol. 181, no. 10, pp. 6923–6933, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Kareva and P. Hahnfeldt, “The emerging ‘hallmarks’ of metabolic reprogramming and immune evasion: distinct or linked?” Cancer Research, vol. 73, no. 9, pp. 2737–2742, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Guo, A. A. Shestov, A. J. Worth et al., “Inhibition of mitochondrial complex II by the anti-cancer agent lonidamine,” The Journal of Biological Chemistry, 2015. View at Publisher · View at Google Scholar
  6. N. Jones, J. Piasecka, A. H. Bryant et al., “Bioenergetic analysis of human peripheral blood mononuclear cells,” Clinical & Experimental Immunology, vol. 182, no. 1, pp. 69–80, 2015. View at Publisher · View at Google Scholar
  7. T. Zal, A. Volkmann, and B. Stockinger, “Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen,” The Journal of Experimental Medicine, vol. 180, no. 6, pp. 2089–2099, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Volkmann, T. Zal, and B. Stockinger, “Antigen-presenting cells in the thymus that can negatively select MHC class II-restricted T cells recognizing a circulating self antigen,” Journal of Immunology, vol. 158, no. 2, pp. 693–706, 1997. View at Google Scholar · View at Scopus
  9. C. Ohnmacht, A. Pullner, S. B. S. King et al., “Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity,” The Journal of Experimental Medicine, vol. 206, no. 3, pp. 549–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Bonifaz, D. Bonnyay, K. Mahnke, M. Rivera, M. C. Nussenzweig, and R. M. Steinman, “Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance,” The Journal of Experimental Medicine, vol. 196, no. 12, pp. 1627–1638, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Mahnke, “Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells,” Blood, vol. 101, no. 12, pp. 4862–4869, 2003. View at Publisher · View at Google Scholar
  12. R. A. Maldonado and U. H. von Andrian, “How tolerogenic dendritic cells induce regulatory T cells,” Advances in Immunology, vol. 108, pp. 111–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Penna, S. Amuchastegui, G. Laverny, and L. Adorini, “Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells,” Journal of Bone and Mineral Research, vol. 22, no. 2, pp. V69–V73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. F. Yates, A. M. Paterson, K. F. Nolan et al., “Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation,” The Journal of Immunology, vol. 179, no. 2, pp. 967–976, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. P. M. Emmer, J. Van Der Vlag, G. J. Adema, and L. B. Hilbrands, “Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness,” Transplantation, vol. 81, no. 10, pp. 1451–1459, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. E. Pedersen, E. G. W. Schmidt, M. Gad, S. S. Poulsen, and M. H. Claesson, “Dexamethasone/1α-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model,” Immunology, vol. 127, no. 3, pp. 354–364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Taner, H. Hackstein, Z. Wang, A. E. Morelli, and A. W. Thomson, “Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival,” American Journal of Transplantation, vol. 5, no. 2, pp. 228–236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson, “Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance,” The Journal of Immunology, vol. 178, no. 11, pp. 7018–7031, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Giannoukakis, B. Phillips, D. Finegold, J. Harnaha, and M. Trucco, “Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients,” Diabetes Care, vol. 34, no. 9, pp. 2026–2032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Benham, H. J. Nel, S. C. Law et al., “Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients,” Science Translational Medicine, vol. 7, no. 290, Article ID 290ra87, 2015. View at Publisher · View at Google Scholar
  21. P. Verginis, H. S. Li, and G. Carayanniotis, “Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells,” Journal of Immunology, vol. 174, no. 11, pp. 7433–7439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. X.-J. Yang, S. Meng, Z. Chun-Fu, H. Jiang, and W.-X. Wu, “Semi-mature MyD88-silenced bone marrow dendritic cells prolong the allograft survival in a rat model of intestinal transplantation,” Chinese Medical Journal, vol. 124, no. 2, pp. 268–272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. B.-M. Fu, X.-S. He, S. Yu et al., “Tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by the activation of antigen-specific CD4+ CD25+ T-regulatory cells,” Experimental and Clinical Transplantation, vol. 7, no. 3, pp. 149–156, 2009. View at Google Scholar · View at Scopus
  24. A. M. Dudek, S. Martin, A. D. Garg, and P. Agostinis, “Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity,” Frontiers in Immunology, vol. 4, article 438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Manavalan, P. C. Rossi, G. Vlad et al., “High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells,” Transplant Immunology, vol. 11, no. 3-4, pp. 245–258, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. J. Wolfle, J. Strebovsky, H. Bartz et al., “PD-L1 expression on tolerogenic APCs is controlled by STAT-3,” European Journal of Immunology, vol. 41, no. 2, pp. 413–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Amodio, R. Sales de Albuquerque, and S. Gregori, “New insights into HLA-G mediated tolerance,” Tissue Antigens, vol. 84, no. 3, pp. 255–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Rebmann, F. D. S. Nardi, B. Wagner, and P. A. Horn, “HLA-G as a tolerogenic molecule in transplantation and pregnancy,” Journal of Immunology Research, vol. 2014, Article ID 297073, 16 pages, 2014. View at Publisher · View at Google Scholar
  29. J. M. Ilarregui, D. O. Croci, G. A. Bianco et al., “Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10,” Nature Immunology, vol. 10, no. 9, pp. 981–991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Rémy, P. Blancou, L. Tesson et al., “Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity,” Journal of Immunology, vol. 182, no. 4, pp. 1877–1884, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Li and B. Shi, “Tolerogenic dendritic cells and their applications in transplantation,” Cellular and Molecular Immunology, vol. 12, no. 1, pp. 24–30, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. I. D. Mascanfroni, A. Yeste, S. M. Vieira et al., “IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39,” Nature Immunology, vol. 14, no. 10, pp. 1054–1063, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. F. W. Velten, K. Duperrier, J. Bohlender, P. Metharom, and S. Goerdt, “A gene signature of inhibitory MHC receptors identifies a BDCA3+ subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro,” European Journal of Immunology, vol. 34, no. 10, pp. 2800–2811, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Jung, R. Sabat, J. Krätzschmar et al., “Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy,” European Journal of Immunology, vol. 34, no. 2, pp. 481–493, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Takai, “Paired immunoglobulin-like receptors and their MHC class I recognition,” Immunology, vol. 115, no. 4, pp. 433–440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Endo, Y. Sakamoto, E. Kobayashi, A. Nakamura, and T. Takai, “Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14515–14520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. R. V. Parry, J. M. Chemnitz, K. A. Frauwirth et al., “CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms,” Molecular and Cellular Biology, vol. 25, no. 21, pp. 9543–9553, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. M. E. Keir, L. M. Francisco, and A. H. Sharpe, “PD-1 and its ligands in T-cell immunity,” Current Opinion in Immunology, vol. 19, no. 3, pp. 309–314, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. T. J. Curiel, S. Wei, H. Dong et al., “Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity,” Nature Medicine, vol. 9, no. 5, pp. 562–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. C. L. Day, D. E. Kaufmann, P. Kiepiela et al., “PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression,” Nature, vol. 443, no. 7109, pp. 350–354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Schmidt, N. Lügering, H.-G. Pauels, K. Schulze-Osthoff, W. Domschke, and T. Kucharzik, “IL-10 induces apoptosis in human monocytes involving the CD95 receptor/ligand pathway,” European Journal of Immunology, vol. 30, no. 6, pp. 1769–1777, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Li-Weber and P. H. Krammer, “The death of a T-cell: expression of the CD95 ligand,” Cell Death and Differentiation, vol. 9, no. 2, pp. 101–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. D. H. Munn, M. D. Sharma, J. R. Lee et al., “Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase,” Science, vol. 297, no. 5588, pp. 1867–1870, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Terness, T. M. Bauer, L. Röse et al., “Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites,” Journal of Experimental Medicine, vol. 196, no. 4, pp. 447–457, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Laouar, F. S. Sutterwala, L. Gorelik, and R. A. Flavell, “Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ,” Nature Immunology, vol. 6, no. 6, pp. 600–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. W. Sun, Q. Wang, L. Zhang et al., “TGF-β1 gene modified immature dendritic cells exhibit enhanced tolerogenicity but induce allograft fibrosis in vivo,” Journal of Molecular Medicine, vol. 80, no. 8, pp. 514–523, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. M. T. Pallotta, C. Orabona, C. Volpi et al., “Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells,” Nature Immunology, vol. 12, no. 9, pp. 870–878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. M. L. Belladonna, C. Volpi, R. Bianchi et al., “Cutting edge: autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells,” Journal of Immunology, vol. 181, no. 8, pp. 5194–5198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Song, P. Yuan, H. Wu et al., “Dendritic cells with an increased PD-L1 by TGF-β induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells,” International Immunopharmacology, vol. 20, no. 1, pp. 117–123, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. D. C. Thomas, F. S. Wong, P. Zaccone, E. A. Green, and M. Wållberg, “Protection of islet grafts through transforming growth factor-β induced tolerogenic dendritic cells,” Diabetes, vol. 62, no. 9, pp. 3132–3142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Nikolic and B. O. Roep, “Regulatory multitasking of tolerogenic dendritic cells—lessons taken from vitamin D3-treated tolerogenic dendritic cells,” Frontiers in Immunology, vol. 4, article 113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Hackstein, T. Taner, A. F. Zahorchak et al., “Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo,” Blood, vol. 101, no. 11, pp. 4457–4463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Zimmer, J. Bouley, M. Le Mignon et al., “A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy,” The Journal of Allergy and Clinical Immunology, vol. 129, no. 4, pp. 1020–1030, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Bros, F. Jährling, A. Renzing et al., “A newly established murine immature dendritic cell line can be differentiated into a mature state, but exerts tolerogenic function upon maturation in the presence of glucocorticoid,” Blood, vol. 109, no. 9, pp. 3820–3829, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. P. L. Vieira, P. Kaliński, E. A. Wierenga, M. L. Kapsenberg, and E. C. De Jong, “Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential,” The Journal of Immunology, vol. 161, no. 10, pp. 5245–5251, 1998. View at Google Scholar · View at Scopus
  57. A. E. Pedersen, M. Gad, M. R. Walter, and M. H. Claesson, “Induction of regulatory dendritic cells by dexamethasone and 1α,25-Dihydroxyvitamin D3,” Immunology Letters, vol. 91, no. 1, pp. 63–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Fedoric and R. Krishnan, “Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction,” Immunology Letters, vol. 120, no. 1-2, pp. 49–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Battaglia, A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper, and M.-G. Roncarolo, “Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients,” The Journal of Immunology, vol. 177, no. 12, pp. 8338–8347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. W. W. J. Unger, S. Laban, F. S. Kleijwegt, A. R. Van Der Slik, and B. O. Roep, “Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1,” European Journal of Immunology, vol. 39, no. 11, pp. 3147–3159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Penna, A. Roncari, S. Amuchastegui et al., “Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3,” Blood, vol. 106, no. 10, pp. 3490–3497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Penna and L. Adorini, “1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation,” Journal of Immunology, vol. 164, no. 5, pp. 2405–2411, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. X. Dong, W. Lutz, T. M. Schroeder et al., “Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 44, pp. 16007–16012, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Martin, B. O'Sullivan, P. Low, and R. Thomas, “Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10,” Immunity, vol. 18, no. 1, pp. 155–167, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Matsumoto, H. Hasegawa, S. Onishi, J. Ishizaki, K. Suemori, and M. Yasukawa, “Protein kinase C inhibitor generates stable human tolerogenic dendritic cells,” The Journal of Immunology, vol. 191, no. 5, pp. 2247–2257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Jiang, O. Bloom, S. Ono et al., “Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation,” Immunity, vol. 27, no. 4, pp. 610–624, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Manicassamy, B. Reizis, R. Ravindran et al., “Activation of β-catenin in dendritic cells regulates immunity versus tolerance in the intestine,” Science, vol. 329, no. 5993, pp. 849–853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Weinberg and N. S. Chandel, “Mitochondrial metabolism and cancer,” Annals of the New York Academy of Sciences, vol. 1177, pp. 66–73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Haschemi, P. Kosma, L. Gille et al., “The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism,” Cell Metabolism, vol. 15, no. 6, pp. 813–826, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Everts and E. J. Pearce, “Metabolic control of dendritic cell activation and function: recent advances and clinical implications,” Frontiers in Immunology, vol. 5, article 203, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. B. Kelly and L. A. O'Neill, “Metabolic reprogramming in macrophages and dendritic cells in innate immunity,” Cell Research, vol. 25, no. 7, pp. 771–784, 2015. View at Publisher · View at Google Scholar
  72. P. A. Kramer, S. Ravi, B. Chacko, M. S. Johnson, and V. M. Darley-Usmar, “A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: implications for their use as bioenergetic biomarkers,” Redox Biology, vol. 2, no. 1, pp. 206–210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. D. O'Sullivan, G. van der Windt, S.-C. Huang et al., “Memory CD8+ T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development,” Immunity, vol. 41, no. 1, pp. 75–88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Quintana, C. Schwindling, A. S. Wenning et al., “T cell activation requires mitochondrial translocation to the immunological synapse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 36, pp. 14418–14423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. C. H. Chang, J. Qiu, D. O'Sullivan et al., “Metabolic competition in the tumor microenvironment is a driver of cancer progression,” Cell, vol. 162, no. 6, pp. 1229–1241, 2015. View at Publisher · View at Google Scholar
  76. E. J. Pearce and B. Everts, “Dendritic cell metabolism,” Nature Reviews Immunology, vol. 15, no. 1, pp. 18–29, 2015. View at Publisher · View at Google Scholar
  77. P. Zaccagnino, M. Saltarella, S. Maiorano et al., “An active mitochondrial biogenesis occurs during dendritic cell differentiation,” International Journal of Biochemistry and Cell Biology, vol. 44, no. 11, pp. 1962–1969, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. J. R. Cubillos-Ruiz, P. C. Silberman, M. R. Rutkowski et al., “ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis,” Cell, vol. 161, no. 7, pp. 1527–1538, 2015. View at Publisher · View at Google Scholar
  79. N. J. MacIver, R. D. Michalek, and J. C. Rathmell, “Metabolic regulation of T lymphocytes,” Annual Review of Immunology, vol. 31, no. 1, pp. 259–283, 2013. View at Publisher · View at Google Scholar
  80. B. Everts, E. Amiel, G. J. W. Van Der Windt et al., “Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells,” Blood, vol. 120, no. 7, pp. 1422–1431, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Nikolic and B. O. Roep, “Regulatory multitasking of tolerogenic dendritic cells—lessons taken from vitamin D3-treated tolerogenic dendritic cells,” Frontiers in Immunology, vol. 4, article 113, Article ID Article 113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. F. Malinarich, K. Duan, R. A. Hamid et al., “High mitochondrial respiration and glycolytic capacity represent a metabolic phenotype of human tolerogenic dendritic cells,” The Journal of Immunology, vol. 194, no. 11, pp. 5174–5186, 2015. View at Publisher · View at Google Scholar
  83. M. L. Belladonna, U. Grohmann, P. Guidetti et al., “Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO,” The Journal of Immunology, vol. 177, no. 1, pp. 130–137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. Q. Yang, J. Wei, L. Zhong et al., “Cross talk between histone deacetylase 4 and STAT6 in the transcriptional regulation of arginase 1 during mouse dendritic cell differentiation,” Molecular and Cellular Biology, vol. 35, no. 1, pp. 63–75, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. H. Hackstein and A. W. Thomson, “Dendritic cells: emerging pharmacological targets of immunosuppressive drugs,” Nature Reviews Immunology, vol. 4, no. 1, pp. 24–34, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. W. Li, Q. Wang, X. Liu et al., “Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice,” Cancer Prevention Research, vol. 8, no. 2, pp. 139–148, 2015. View at Publisher · View at Google Scholar
  87. L. A. J. O'Neill and D. Grahame Hardie, “Metabolism of inflammation limited by AMPK and pseudo-starvation,” Nature, vol. 493, no. 7432, pp. 346–355, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. N. Kudo, A. J. Barr, R. L. Barr, S. Desai, and G. D. Lopaschuk, “High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase,” The Journal of Biological Chemistry, vol. 270, no. 29, pp. 17513–17520, 1995. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Abu-Elheiga, M. M. Matzuk, K. A. H. Abo-Hashema, and S. J. Wakil, “Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-coa carboxylase 2,” Science, vol. 291, no. 5513, pp. 2613–2616, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Hewison, L. Freeman, S. V. Hughes et al., “Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells,” The Journal of Immunology, vol. 170, no. 11, pp. 5382–5390, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Matasić, A. B. Dietz, and S. Vuk-Pavlović, “Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells,” Journal of Leukocyte Biology, vol. 66, no. 6, pp. 909–914, 1999. View at Google Scholar · View at Scopus
  93. L. Piemonti, P. Monti, P. Allavena et al., “Glucocorticoids affect human dendritic cell differentiation and maturation,” The Journal of Immunology, vol. 162, no. 11, pp. 6473–6481, 1999. View at Google Scholar · View at Scopus
  94. R. Korhonen, A. Lahti, M. Hämäläinen, H. Kankaanranta, and E. Moilanen, “Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages,” Molecular Pharmacology, vol. 62, no. 3, pp. 698–704, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. H. J. Wu, Y. Lo, D. Luk, C. S. Lau, L. Lu, and M. Y. Mok, “Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function,” Clinical Immunology, vol. 156, no. 1, pp. 43–57, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. P. K. Majumder, P. G. Febbo, R. Bikoff et al., “mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways,” Nature Medicine, vol. 10, no. 6, pp. 594–601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. R. T. Fischer, H. R. Turnquist, Z. Wang, D. Beer-Stolz, and A. W. Thomson, “Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8+ T cells in vitro and in vivo,” Transplant Immunology, vol. 25, no. 1, pp. 20–26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. R. J. Creusot, N. Giannoukakis, M. Trucco, M. J. Clare-Salzler, and C. G. Fathman, “It's time to bring dendritic cell therapy to type 1 diabetes,” Diabetes, vol. 63, no. 1, pp. 20–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. C. M. U. Hilkens and J. D. Isaacs, “Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?” Clinical and Experimental Immunology, vol. 172, no. 2, pp. 148–157, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Li, G. Romain, A.-L. Flamar et al., “Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells,” The Journal of Experimental Medicine, vol. 209, no. 1, pp. 109–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Maggi, C. Schafer, G. Ubilla-Olguín, D. Catalán, K. Schinnerling, and J. C. Aguillón, “Therapeutic potential of hyporesponsive CD4+ T cells in autoimmunity,” Frontiers in Immunology, vol. 6, article 488, 2015. View at Publisher · View at Google Scholar